NAT2 and tuberculosis: The PBPK model for oral administration was therefore coupled with a pharmacodynamic (PD) model of mycobacterial growth in human lungs to analyze the influence of the NAT2 phenotype, INH dose, and administration intervals on the efficacy and toxicity of INH-based tuberculosis treatment.